Streetbeat News

ENLV

Enlivex Therapeutics Ltd.

https://www.enlivex.com

Industry

Biotechnology

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

EF Hutton has initiated coverage on Enlivex Therapeutics with a Buy rating and set a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:07 pm

Enlivex has received authorization from the Israeli Ministry of Health to initiate a Phase I clinical trial for Allocetra in patients with psoriatic arthritis.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:08 pm

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) has dosed the first patient in a Phase I/II trial for AllocetraTM, targeting thumb osteoarthritis. This trial aims to evaluate the safety and efficacy of AllocetraTM in up to 46 patients, with no current FDA-approved therapies for this condition.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:07 pm

Enlivex Therapeutics released interim data from its Phase I/II AllocetraTM trial, showing a 64% average pain reduction, 33% of patients reported pain resolution, and 89% did not proceed with knee replacement surgery.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:05 pm

HC Wainwright & Co. has maintained its Buy rating on Enlivex Therapeutics (NASDAQ:ENLV) but has lowered the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 10:13 am

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) has received regulatory authorization from the Israeli Ministry of Health to initiate a Phase I/II trial for Allocetra™ in treating thumb osteoarthritis. This is the first study of Allocetra™ in thumb osteoarthritis, a condition with no FDA-approved therapy, and follows ongoing trials in knee osteoarthritis.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:43 pm

Enlivex Therapeutics has entered into an agreement with an institutional investor for the issuance and sale of 3,571,429 ordinary shares and milestone-linked warrants. The deal includes an upfront payment of $5 million and could generate up to an additional $10 million upon full exercise of the warrants.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:15 pm

Enlivex Therapeutics has entered into an agreement for a registered direct offering of 3.57 million ordinary shares and milestone-linked warrants, raising $5 million upfront and potentially up to $10 million from warrant exercises.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:14 pm

Clever Leaves Holdings Inc. announced its decision to voluntarily delist from Nasdaq, causing a 60% drop in its shares. Other stocks moved significantly in Monday's session, with Deciphera Pharmaceuticals surging 73% after an acquisition announcement, and various companies like Collective Audience and ImmunityBio also seeing substantial gains. Losers included Annovis Bio, down 57% after disappointing trial results, and Addex Therapeutics, falling 48.8% due to a failed epilepsy study.

Portfolio Pulse from Avi Kapoor

April 29, 2024 | 5:04 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Enlivex Therapeutics (NASDAQ:ENLV) with a maintained price target of $7.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 10:33 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.